Vaxcyte (PCVX) Cash from Operations (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Cash from Operations of 280625000.0 for Q1 2026, down 68.77% year-over-year from 898650718.37 in Q1 2025, and down 24.82% quarter-over-quarter from 224832000.0 in Q4 2025.
Powered by 
Analysis
Vaxcyte (PCVX) Cash from Operations (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Cash from Operations for 8 consecutive years, with 280625000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 68.77% year-over-year to 280625000.0; the TTM figure through Mar 2026 stood at 769928000.0 (down 67.46% YoY), while the FY2025 annual figure was 655577000.0, down 44.84% from the prior year.
- Cash from Operations fell to 280625000.0 in Q1 2026 per PCVX's latest filing, from 224832000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27702000.0 in Q1 2022 and bottomed at 280625000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 109189176.47 across 5 years, with a median of 111401000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 13.52% in 2024 and fell as far as 233.66% in 2024.
- Vaxcyte's Cash from Operations stood at 65221000.0 in 2022, then sank by 97.5% to 128810000.0 in 2023, then increased by 13.52% to 111401000.0 in 2024, then tumbled by 101.82% to 224832000.0 in 2025, then fell by 24.82% to 280625000.0 in 2026.
- Business Quant data shows PCVX's Cash from Operations at 280625000.0 in Q1 2026, 224832000.0 in Q4 2025, and 143305000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - | -232.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -232.47 Mn |
| Mar 31, 2026 | -280.63 Mn |
| Dec 31, 2025 | -224.83 Mn |
| Sep 30, 2025 | -143.31 Mn |
| Jun 30, 2025 | -121.17 Mn |
| Mar 31, 2025 | -166.27 Mn |
| Dec 31, 2024 | -111.40 Mn |
| Sep 30, 2024 | -60.71 Mn |
| Jun 30, 2024 | -121.39 Mn |
| Mar 31, 2024 | -159.12 Mn |
| Dec 31, 2023 | -128.81 Mn |
| Sep 30, 2023 | -57.55 Mn |
| Jun 30, 2023 | -62.74 Mn |
| Mar 31, 2023 | -47.69 Mn |
| Dec 31, 2022 | -65.22 Mn |
| Sep 30, 2022 | -38.55 Mn |
| Jun 30, 2022 | -39.13 Mn |
| Mar 31, 2022 | -27.70 Mn |
| Dec 31, 2021 | -51.09 Mn |
| Sep 30, 2021 | -28.42 Mn |